[Medical treatment of glaucoma].
OBJECTIVE
this review aims to establish the easiest possible diagram to aid the ophthalmologist in the management of the numerous antiglaucomatous agents that have been increasing our therapeutic group.


METHODS
we have analyzed the indications, advantages and inconveniences of the medical treatment successively and have reviewed the criteria used to choose a specific drug based on glaucoma severity, general clinical history of the patient, tolerance, local and general adverse effects.


RESULTS
finally, we have also considered the ease of compliance, validity of associations and influence of these factors in the patient's quality of life.


CONCLUSIONS
the final therapeutic outline is really an index that aims to facilitate a correct use standard.
García Sánchez
J
J
Universidad Complutense de Madrid, Hospital Clínico de San Carlos, Madrid.
García Feijoó
J
J
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D010277:Parasympathomimetics / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D010277:Parasympathomimetics; D011453:Prostaglandins